Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAJESH KUMAR DAVIT

Allopathic & Osteopathic Physicians Family Medicine

NPI
1194745612
CMS profile
8993
Location
CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$20.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Gift $20.00 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $20.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAJESH KUMAR DAVIT

NPI 1194745612 · CMS profile ID 8993

Allopathic & Osteopathic Physicians / Family Medicine

CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1194745612?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAJESH KUMAR DAVIT, NPI 1194745612, CMS profile ID 8993. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1194745612?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). RAJESH KUMAR DAVIT, NPI 1194745612, CMS profile ID 8993. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1194745612?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
RAJESH KUMAR DAVIT, NPI 1194745612, CMS profile ID 8993, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1194745612?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $20.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $20.0006/01/2021 Gift No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833593825 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $121.33 10
PY2021 $20.00 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021
Generated from
OP_DTL_GNRL_PGYR2021_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $262.50 1
PY2023 Principal investigator $2,362.50 2
PY2022 Principal investigator $32,230.30 12
PY2021 Principal investigator $630,825.65 54
PY2020 Principal investigator $1,065,139.88 36
PY2019 Principal investigator $273,518.61 46

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

46 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $801.57 12/05/2019 Non-covered Recipient Entity
Sterling Research Group Ltd
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671680443
Principal investigator 1 PFIZER INC. $1,870.33 12/05/2019 Non-covered Recipient Entity
Sterling Research Group Ltd
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685681
Principal investigator 1 PFIZER INC. $801.57 11/22/2019 Non-covered Recipient Entity
Sterling Research Group Ltd
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671680785
Principal investigator 1 PFIZER INC. $2,671.90 11/22/2019 Non-covered Recipient Entity
Sterling Research Group Ltd
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685613
Principal investigator 1 PFIZER INC. $734.83 11/06/2019 Non-covered Recipient Entity
STERLING RESEARCH GROUP INC
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED STUDY TO ASSESS THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF BIVALENT RLP2086 WHEN ADMINISTERED AS A 2DOSE REGIMEN AND A FIRSTINHUMAN STUDY TO DESCRIBE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF A BIVALENT RLP2086CONTAINING PENTAVALENT VACCINE MENABCWY IN HEALTHY SUBJECTS10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 671670549
Principal investigator 1 PFIZER INC. $801.57 11/02/2019 Non-covered Recipient Entity
Sterling Research Group Ltd
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671680825
Principal investigator 1 PFIZER INC. $1,870.33 11/02/2019 Non-covered Recipient Entity
Sterling Research Group Ltd
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685679
Principal investigator 1 PFIZER INC. $1,603.14 10/23/2019 Non-covered Recipient Entity
Sterling Research Group Ltd
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671680441
Principal investigator 1 PFIZER INC. $4,275.04 10/23/2019 Non-covered Recipient Entity
Sterling Research Group Ltd
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685743
Principal investigator 1 PFIZER INC. $801.57 10/09/2019 Non-covered Recipient Entity
Sterling Research Group Ltd
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671680873
Principal investigator 1 PFIZER INC. $3,939.96 10/09/2019 Non-covered Recipient Entity
Sterling Research Group Ltd
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685813
Principal investigator 1 PFIZER INC. $5,302.50 09/20/2019 Non-covered Recipient Entity
Sterling Research Group Ltd
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685615
Principal investigator 1 PFIZER INC. $2,384.80 09/18/2019 Non-covered Recipient Entity
STERLING RESEARCH GROUP INC
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED STUDY TO ASSESS THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF BIVALENT RLP2086 WHEN ADMINISTERED AS A 2DOSE REGIMEN AND A FIRSTINHUMAN STUDY TO DESCRIBE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF A BIVALENT RLP2086CONTAINING PENTAVALENT VACCINE MENABCWY IN HEALTHY SUBJECTS10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 671673725
Principal investigator 1 PFIZER INC. $1,720.69 08/20/2019 Non-covered Recipient Entity
Sterling Research Group Ltd
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685747
Principal investigator 1 PFIZER INC. $8,540.52 08/06/2019 Non-covered Recipient Entity
Sterling Research Group Ltd
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685745
Principal investigator 1 PFIZER INC. $360.62 07/24/2019 Non-covered Recipient Entity
STERLING RESEARCH GROUP INC
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED STUDY TO ASSESS THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF BIVALENT RLP2086 WHEN ADMINISTERED AS A 2DOSE REGIMEN AND A FIRSTINHUMAN STUDY TO DESCRIBE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF A BIVALENT RLP2086CONTAINING PENTAVALENT VACCINE MENABCWY IN HEALTHY SUBJECTS10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 671654453
Principal investigator 1 PFIZER INC. $4,845.00 07/20/2019 Non-covered Recipient Entity
Sterling Research Group Ltd
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671680379
Principal investigator 1 PFIZER INC. $26,550.18 07/13/2019 Non-covered Recipient Entity
Sterling Research Group Ltd
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685677
Principal investigator 1 PFIZER INC. $522.50 07/10/2019 Non-covered Recipient Entity
Sterling Research Group Ltd
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671680787
Principal investigator 1 PFIZER INC. $3,810.69 07/10/2019 Non-covered Recipient Entity
Sterling Research Group Ltd
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685617
Principal investigator 1 PFIZER INC. $500.95 07/08/2019 Non-covered Recipient Entity
Sterling Research Group Ltd
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685485
Principal investigator 1 PFIZER INC. $1,567.50 06/25/2019 Non-covered Recipient Entity
Sterling Research Group Ltd
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671654451
Principal investigator 1 PFIZER INC. $21,440.35 06/25/2019 Non-covered Recipient Entity
Sterling Research Group Ltd
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685815
Principal investigator 1 PFIZER INC. $100.19 06/24/2019 Non-covered Recipient Entity
Sterling Research Group
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685553
Principal investigator 1 PFIZER INC. $100.19 06/11/2019 Non-covered Recipient Entity
Sterling Research Group
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685277
Principal investigator 1 PFIZER INC. $9,205.52 06/06/2019 Non-covered Recipient Entity
Sterling Research Group Ltd
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671656897
Principal investigator 1 PFIZER INC. $20,750.44 06/05/2019 Non-covered Recipient Entity
Sterling Research Group Ltd
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685817
Principal investigator 1 PFIZER INC. $300.57 05/28/2019 Non-covered Recipient Entity
Sterling Research Group
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685275
Principal investigator 1 PFIZER INC. $7,737.76 05/24/2019 Non-covered Recipient Entity
Sterling Research Group Ltd
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671654601
Principal investigator 1 PFIZER INC. $22,339.32 05/24/2019 Non-covered Recipient Entity
Sterling Research Group Ltd
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685953
Principal investigator 1 PFIZER INC. $200.38 05/20/2019 Non-covered Recipient Entity
Sterling Research Group
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685279
Principal investigator 1 PFIZER INC. $21,346.56 05/08/2019 Non-covered Recipient Entity
Sterling Research Group Ltd
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671657823
Principal investigator 1 PFIZER INC. $200.38 05/08/2019 Non-covered Recipient Entity
Sterling Research Group
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685481
Principal investigator 1 PFIZER INC. $20,739.75 05/08/2019 Non-covered Recipient Entity
Sterling Research Group Ltd
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671686015
Principal investigator 1 PFIZER INC. $500.95 04/29/2019 Non-covered Recipient Entity
Sterling Research Group
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685549
Principal investigator 1 PFIZER INC. $23,125.44 04/24/2019 Non-covered Recipient Entity
Sterling Research Group Ltd
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685951
Principal investigator 1 PFIZER INC. $200.38 04/16/2019 Non-covered Recipient Entity
Sterling Research Group Ltd
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671684205
Principal investigator 1 PFIZER INC. $601.14 04/16/2019 Non-covered Recipient Entity
Sterling Research Group
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685551
Principal investigator 1 PFIZER INC. $6,075.00 04/10/2019 Non-covered Recipient Entity
Sterling Research Group Ltd
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671657997
Principal investigator 1 PFIZER INC. $30,979.32 04/10/2019 Non-covered Recipient Entity
Sterling Research Group Ltd
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685949
Principal investigator 1 PFIZER INC. $701.33 04/08/2019 Non-covered Recipient Entity
Sterling Research Group
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671685483
Principal investigator 1 Ironwood Pharmaceuticals, Inc $1,543.20 04/05/2019 Non-covered Recipient Entity
STERLING RESEARCH GROUP, LTD.
RDEA594-401 No dispute reported 06/30/2026 705396269
Principal investigator 1 Ironwood Pharmaceuticals, Inc $4,210.90 04/05/2019 Non-covered Recipient Entity
STERLING RESEARCH GROUP, LTD.
RDEA594-401 No dispute reported 06/30/2026 705396271
Principal investigator 1 PFIZER INC. $200.38 02/13/2019 Non-covered Recipient Entity
Sterling Research Group
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671686017
Principal investigator 1 PFIZER INC. $400.76 02/12/2019 Non-covered Recipient Entity
Sterling Research Group Ltd
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671654697
Principal investigator 1 PFIZER INC. $4,240.64 01/10/2019 Non-covered Recipient Entity
STERLING RESEARCH GROUP LTD
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 26WEEK MULTICENTER STUDY WITH A 78WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MO No dispute reported 06/30/2026 671654701